A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Small Cell Lung Cancer|Small Cell Lung Carcinoma
DRUG: ABT-263
Safety assessment, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing|Dose limiting toxicity determination, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing|Maximum tolerated dose determination, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing|Pharmacokinetic profile evaluation, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
Extended safety assessment at the recommended Phase 2 dose, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing|Preliminary efficacy assessment, Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.